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Abstract. The focus of this mini-review is to identify non-toxic
compounds isolated from natural sources (plants) that exhibit
specific activity against efflux pumps of specific multidrug-
resistant (MDR) cancer cell lines, inhibit proliferation of the
MDR cancer cell lines and inhibit the activity of overexpressed
efflux pumps of the MDR cancer cell line. 
Therapy of cancer, if not completely effective, results in the
overexpression of genes that code for efflux pumps that
extrude the noxious agent (anticancer drug) before it reaches
its intended target of the cancer cell (1). The overexpressed
efflux pump renders the cancer cell immune to not only the
initial drug used in therapy but to a wide range of unrelated
noxious compounds (1). The arising of this multidrug-
resistant (MDR) phenotype makes therapy highly problematic
and the end result is that the patient succumbs to the disease
(1). Therefore, it is the consensus of many that therapy of
MDR cancer may succeed if the responsible efflux pump is
inhibited from its activity, therefore, affording the increased
concentration of anticancer drug to a level consistent with its
toxic targeted action needed to kill the cancer cell. To this
extent, over 100,000 synthetic compounds for activity against
the known efflux pumps of cancer cell types have been
screened by the National Cancer Institute (USA) and, to date,
not a single inhibitor has found its way toward successful
therapy of MDR cancer. In fact, because normal counter type
cells have a fully functional efflux pump, albeit at a much
lower level of activity, clinical trials with selected efflux
pump inhibitors have produced high toxicity and even death.
During the past two decades, traditional medicine has
become a source for the identification of plants that harbor
compounds that may have important potential for the therapy
of cancer. With respect to the laboratory of one of the
authors of this mini-review (JM), literally, hundreds of plants
have been studied for their activity against specific targets
of the cancer cell and it is the focus of this mini-review to
identify selected compounds that have no toxicity at the level
of their in vitro study and which have activity against
proliferation or induction of the apoptotic mechanism or the
efflux pump responsible for the phenotype of the MDR
cancer cell.
Targets of MDR Cancer Cells
Proliferation. Proliferation is affected by many drugs and,
although the search for non-toxic compounds that inhibit
proliferation was initiated more than 60 years ago, remains
the focus of most studies; however, the inhibition of
proliferation by compounds isolated from natural sources
will not be discussed here at the level of its mechanism.
Rather, suffice to say that our observations for anti-
proliferative activity as presented in the text remain, for the
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most part, not completely understood. 
Apoptosis. Programmed cell death or apoptosis maintains
homeostasis; furthermore, it has a major impact on the
evolution of organs. However, defect in apoptosis can cause
cancer and the suppression of apoptosis during carcinogenesis
may play a crucial role in the development of some cancer
types (2). Apoptosis is characterized by different
morphological changes, such as cell membrane blebbing, cell
shrinkage, nuclear fragmentation, chromatin condensation and
chromosomal DNA fragmentation (3, 4). In order to promote
phagocytosis of apoptotic cells by macrophages, apoptotic
cells present specific membrane morphologies to activate this
process. One of these changes is the translocation of
phosphatydilserine from the inside of the cell to the outer
surface, followed by membrane blebbing and small vesicles
called apoptotic bodies (5). In the early stages of apoptosis,
caspases are activated in order to initiate and accomplish the
cleavage of essential cellular components. Caspases can be
activated by either of the two known apoptotic signaling
pathways, i.e. intrinsic (mitochondria-mediated) and extrinsic
(death receptor-mediated) pathways. In addition, there is a
third pathway, described as intrinsic endoplasmic reticulum
(ER) pathway, which involves the ER and is based on the
oxidative stress response (6). These pathways and their
components are targets for agents that are designed to kill
cancer cells and, because many compounds isolated from
botanical sources have effects on cancer cells that display
qualitative and quantitative properties that differ significantly
from their normal counterpart cells, we have investigated the
potential effect of compounds isolated from natural sources to
induce apoptosis in cancer cells and distinguish these effects
from effects of the agents on overexpressed efflux pumps that
contribute to the multidrug resistance of some cancers. 
Efflux Pumps
The major mechanism responsible for the MDR phenotype
of MDR cancer cells is the overexpression of ATP-dependent
transporters that belong to the ATP-binding cassette (ABC)
family. These ATP-dependent transporters extrude noxious
agents from the cancer cell before they reach their intended
targets. These transporters are termed efflux pumps (EPs)
and three major types have been identified for specific
cancer cell lines: the ABCB, which has been the most
studied of the three EPs, also known as ABCB1 or MDR1 or
P-glycoprotein (Pgp1), the ABCC, also known as ABCC1 or
MRP1 or ABCC2 or MRP2 or, infrequently, specified as
ABCC3–6 and ABCC10–11, as well as the ABCG also
known as ABCG2 or MXR or BCRP. The overexpression of
these ABC EPs and the resistance of MDR cancer cells to
anticancer agents are of obvious importance for
chemotherapy of MDR cancer. 
Pgp1 (ABCB1/MDR1) was isolated from Chinese hamster
cell lines in the laboratory of Victor Ling in 1976 and its
amino acid sequence determined by the same investigating
laboratory in 1989 (7). From these and other studies
involving the human Pgp1, the structure of Pgp1, as it may
appear on the plasma membrane of an MDR cancer cell, is
presented by Figure 1. 
Briefly, Pgp1 is a 170-kDa transmembrane protein that
consists of two halves; the N-terminal half of the molecule
contains 6 transmembrane domains that is followed by a
large cytoplasmic domain with an ATP-binding site and,
then, a second section with 6 transmembrane domains and
an ATP-binding site that has amino acid similarity with the
first half of the polypeptide. The substrate binding sites are
formed by the transmembrane domains. The binding of the
substrate takes place simultaneously with the binding of
ATP and its hydrolysis. Hydrolysis of ATP alters the
conformation of the Pgp1 and the bound substrate is
released to the surface of the cell. The release of the
substrate results in the restoration of Pgp1 conformation that
is now ready to accept another noxious molecule for binding
and another ATP for hydrolysis. 
The inhibition of Pgp1 can occur via three pathways: (i)
Direct binding of the inhibitor by the substrate binding site
of the Pgp1 domain. Binding may be competitive, meaning
that, as the concentration of the inhibitor is increased, the
greater the probability that noxious agent remains in the
cytoplasm of the cell, or, it may be non-competitive, which
means that the affinity of the inhibitor for the substrate
binding site is significantly greater than that of the noxious
substrate. Irreversible binding of the inhibitor, although
possible, is not useful since the same irreversible binding
would take place with Pgp1 proteins of normal cells, thus
compromising the life of the patient. (ii) Inhibition of the
ATP binding domain denying the conformational changes
needed for translocation of the noxious substrate. (iii)
Inhibition of ATP synthesis from glycolysis within the MDR
cancer cell. Although this latter path may also affect normal
counterpart cells, because most cancer cells have impaired
mitochondria, ATP sources are primarily glycolytic, normal
cells may not be as severely affected as the MDR cancer cell. 
Efflux Pump Models Used for the 
Investigations Described in this Mini-review
A cell line used for determination of effects of compounds
from natural sources on efflux is a murine lymphoma cell
that has been transfected with the human MDR1 gene that
codes for Pgp1 (9). It is important to note that the parental
mouse lymphoma cell line has its own efflux pump.
However, the sensitivity of the method used for determining
the effects of a compound on the retention of an anticancer
drug (efflux assay employing the fluorescent substrate
rhodamine 123 and its assay via flow cytometry) is below
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the threshold of detection. Hence, the effects noted are
directly related to those on the efflux of rhodamine 123 by
the presence of the human MDR1 gene that has been
transfected into the mouse lymphoma cell line. 
An additional method that is fully automated has been
developed by our laboratory for the measurement of efflux
of the fluorescent substrate ethidium bromide. This method,
completely described by Spengler et al. (10) provides real-
time data on influx/efflux parameters under defined
conditions of temperature, time, concentrations and
physiological constituents of the media, such as pH, ionic
strength, etc. Examples of data obtained from flow cytometry
and ethidium bromide methods are presented in Figure 2.
Activity of Non-toxic Compounds Isolated 
from Natural Sources (Plants) on 
MDR Cancer Properties
Traditional medicine is now widely considered for the
identification of plants that are known to have medicinal
qualities. Because, for almost all cases, the remedial activity
of the untreated plant is moderate to nominal for specific
pathologies due to the limitations imposed by the largess of
plant that must be ingested, the need for isolation of the
responsible compound and subsequent medicinal chemistry
approaches must be taken. With respect to our two plus
decades’ attention to plant sources for compounds that may
have significant potential for therapy of MDR, the following
sections identify the plant source, the identity of the
compound isolated and the property of the MDR cancer cell
affected (proliferation, apoptotic mechanism, efflux pumps). 
Terpenoids: Diterpenes and Triterpenes
Diterpenes and Triterpenes are classes of chemical
compounds composed of two and three terpene units,
respectively (Figure 3 – example of a triterpene) with the
molecular formula C20H32 and C30H48, respectively and
are made by animals, plants and fungi.
This class of compounds contains members with
biological activities against two of the most important
diseases: multidrug-resistant tuberculosis (11-13) and
multidrug-resistant cancer (14, 15). Because the triterpene
structure is central to all steroids, ecdysteroids produced by
plants and insects have been studied for their anticancer
properties as well (16-18). Derivatives of anticancer
triterpenes have also received attention (19). The anticancer
properties of specific diterpenes and triterpenes are
inhibition of the replication of cancer cells by affecting the
S phase of DNA synthesis (20) supposedly by inhibiting
DNA polymerase activity (21), activating the apoptotic
pathway (20-23) and inhibiting the activity of the efflux
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Figure 1. Theoretical function of Pgp and its location on the plasma membrane. (a) Ribbon-like structure of P-glycoprotein in a unit plasma
membrane. ATP (red) and ADP (blue) molecules present in the cytoplasm and two P-gp substrate/inhibitor molecules (black) are in the extracellular
space. N-terminal transmembrane domain and nucleotide-binding domain are colored red and yellow, respectively, and the C-terminal
transmembrane domain and nucleotide-binding domain are violet and magenta, respectively. The bound QZ59-SSS inhibitor in the transmembrane
(TM) region is shown as a stick model in black. The dashed black circle area is proposed to be one of the portals for entry of substrates or
modulators directly from the membrane. (b) Model of human P-gp based on the structure of S. aureus SAV1866 bound to ADP and open to the
extramembrane space (PDB: 2HYD). Two bound ADP molecules are shown in black. The color code follows that in (a) (8).
pump Pgp1 of cancer cell lines (14-23). The inhibition of
DNA synthesis by direct inhibition of DNA polymerase and
induction of apoptosis are important anticancer targets being
affected by some diterpenes and triterpenes. However, it is
the effect of this class of compounds on the activity of Pgp1
(the main efflux pump of most multidrug-resistant cancer
cells responsible for the multidrug-resistant phenotype) that
deserves major attention given that, by inhibiting the pump,
the cancer cell becomes susceptible to cytotoxic drugs to
which it was initially resistant. Non-cancer cells have the
same efflux pump that is overexpressed by multidrug-
resistant cancer cells. Consequently, the efflux pump
activities of terpenoids would be expected to produce
toxicity against normal cells. However, the concentrations
that are proven to be effective in vitro for the inhibition of
the efflux pump of cancer cells, whenever studied, have
expressed little or no cytotoxic activity against normal cells.
Nevertheless, because the efflux pump of normal cells will
similarly be affected by the terpenoid compound, one would
expect that the adjuvant use of the terpenoid would promote
an even greater negative effect of the anticancer drug
against normal cells. Perhaps, this negative effect can be
acceptable if the activity of the anticancer agent is effective
against multidrug-resistant cancer, which would make
therapy of multidrug-resistant cancer less problematic or
even successful. 
Sources of Important Terpenoids with High
Potential for Therapy of Multidrug-resistant
Cancers
1. Carpobrotus edulis. During Professor Molnar’s visit to my
home (L. Amaral) in 2001 and one of the many walks along
the coastal cliffs of Cascais, Portugal, a particular plant “stole”
his attention from our discussion of future research plans and
the role of his Cost Action B16 recently funded by the
European Commission. As one would have it, the specific plant
that drew his attention was prominently displayed at the edge
of a cliff some 50 meters above the pounding surf. The
precarious position of this plant did not faze Professor Molnar;
he approached it and examined it for he had never seen this
plant before. He asked me if I knew the species and I
responded that, although I did not know its name, the entire
coastal area of Portugal is inundated with this plant and that
there was no need to take any further risk if he had an interest
in the plant. In a much safer area few meters away, the plant
was in abundance and Professor Molnar took a few samples
that consisted of the yellow flower, fleshy stem and roots
supposedly for further study. A few weeks after his return to
Szeged, Hungary, he called me and excitedly told me that the
methanol extract caused his cell model of multidrug-resistant
mouse lymphoma cells transfected with the gene that codes for
the human efflux pump protein Pgp1to become fully
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Figure 2. Examples of data obtained from flow cytometry and ethidium bromide methods. (a) Flow cytometry: The accumulation of rhodamine 123
by parental mouse lymphoma cells (PAR) is at the extreme right of the figure; that of the mouse lymphoma cell transfected with the human MDR 1
gene is at the extreme left of the figure. The addition of the efflux pump inhibitor verapamil to the MDR cell line shifts the accumulation of rhodamine
123 towards that of the PAR. This shift is interpreted to show that the fluorescent rhodamine 123 is now retained and approximates that of the PAR.
(b) Example of efflux data obtained from the ethidium bromide method: Mouse lymphoma cells transfected with the human MDR 1 gene are
incubated with the efflux pump substrate ethidium bromide with and without the efflux pump inhibitors verapamil or reserpine. Note that these
agents increase the retention of ethidium bromide above that than the control lacking these inhibitory agents.
susceptible to doxyrubicin, a cancer drug to which the hybrid
cell line was initially resistant via the overexpression of its
efflux pump. Knowing that my assistant’s father Professor
Viveiros was Portugal’s premier botanist and Professor
Emeritus of the University of Lisbon, I asked his son Dr.
Miguel Viveiros if his father could identify the plant and
provide as much information as possible. The plant was
identified by Professor Viveiros as C. edulis, a member of the
Aizoaceae family and, hence, a potential source of alkaloids
with neuroleptic activity (34). It is about a common, nuisance
plant that grows on the coast of Portugal and has its origins in
coastal areas of South Africa where it is known as “Hottentot-
fig” since its fig-like fruit is edible. The species is represented
by two varieties one that produces a yellow flower and the
other a purple flower. Cross pollination is common and the
hybrid products are indistinguishable from the purple yielding
variety. However, the degree of successful frequency of hybrids
is dependent upon the salinity of the coastal soil (35). The
information provided perked our interest in Portugal since the
neuroleptic thioridazine had been shown by Amaral’s group
to have remarkable in vitro (36) and ex vivo activity (37).
Thus, a joint study was undertaken between the Molnar and
Amaral group that would examine the methanol extract for
properties against multidrug-resistant cancer and multidrug-
resistant Mycobacterium tuberculosis and then isolate the
active compounds and determine their mode of action(s).
Briefly, the results of the cancer component of the study (38)
show that the extract is non-toxic at concentrations that
inhibit a verapamil-sensitive efflux pump of the L5178 mouse
T cell lymphoma cell line, thereby rendering these multidrug-
resistant cells susceptible to anticancer drugs. These non-toxic
concentrations of the methanol extract also prime THP-1
human monocyte-derived macrophages to kill ingested
Staphylococcus aureus, promote the release of lymphokines
associated with cellular immune functions and induce the
proliferation of THP-1 cells within 1 day of exposure as is
the case with phytohaemagglutinin. The potential role of the
compound(s) isolated from Carpobrotus edulis in cancer
biology and related immunological events during
development of cancer was intriguing and prompted a study
that would isolate the biologically active compounds of the
extract and study them in detail with respect to inhibitory
properties, such as replication, induction of apoptosis and
inhibition of the Pgp1 efflux pump responsible for resistance
of multidrug-resistant cancer cell lines. This study involved
a bioassay-guided separation protocol, including the testing
of the extracts, fractions and pure compounds for their ability
to inhibit P-glycoprotein responsible for multidrug resistance
of the mouse lymphoma cells containing the human efflux
pump gene MDR1 and led to the isolation of seven
compounds from the chloroform and ethyl acetate soluble
fractions of the methanolic extract of Carpobrotus edulis. The
compounds were identified by 1-Dimension, 2-Dimension
NMR and MS investigations as triterpenes (beta-amyrin,
uvaol and oleanolic acid), monogalactosyldiacylglycerol,
catechin, epicatechin and procyanidin B5. The triterpene
uvaol was the most effective, non-toxic and promising
compound for development as an adjunct to doxyrubicin
therapy of multidrug-resistant cancer (39). 
2. Euphorbia portlandica. The genus Euphorbia contains
almost 1,600 species characterized by the presence of white
milky, usually toxic, latex. Nevertheless, this group of plants
has been the subject of intense phytochemical research during
recent years due to the wide-spread use of its members in
traditional medicine. The compounds isolated from its extracts
include: flavanoids, terpenoids, alkanes, amino acids and
alkaloids many of which have shown potential in the therapy
of important pathologies. Euphorbia portlandica, a species of
flowering plant, belongs to this family and is endemic to coasts
of Western Europe ranging from Portugal, the northern coasts
of Spain and France and as far north as Scotland. The first
report of anticancer properties of compounds isolated from a
methanol extract of the whole plant of Euphorbia portlandica
was made in 2004 from the collaboration between Professor
Maria-Jose Ferreira of the University of Lisbon and Professor
Joseph Molnar (40). The active compounds were identified as
diterpenes (5'beta,9'alpha,10'alpha)-7-0-(3alpha-methoxy-
8'(12')-drimen-11'-yl)-scopoletin, designated driportlandin
(compound 1) and a new abietane quinoid diterpene 16-
hydroxy-abieta-8,12-diene-11,14-dione, named portlanquinol
(compound 2). Although both compounds 1 and 2 were found
to reverse the resistance of mouse lymphoma cells transfected
with the Pgp1 gene, compound 2 was found to be toxic. In
2006, further collaboration between Joseph Molnar and Maria-
Jose Ferreira resulted in the isolation and characterization of
12 tetracyclic triterpenes from an acetone extract of Euphorbia
portlandica (41). The new triterpenes were shown to reverse
the resistance of the mouse lymphoma cell line model (42). 
Additional terpenoids from the genus Euphorbia have been
isolated, identified, characterized and examined regarding their
biological properties by the Molnar-Ferreira collaboration and
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Figure 3. Hopane: An example of a pentacyclic triterpene.
each has been shown to have distinct properties that inhibited
replication, induced apoptosis and inhibited the efflux pump
machinery of the mouse lymphoma cell line transfected with
the human gene that codes for the Pgp1 transporter (28, 43,
44). These studies indicate that the genus Euphorbia is a rich
source of terpenoid compounds that have important potential
for therapy of multidrug-resistant cancer. Because this genus
contains almost 1,600 species, the interested reader has an
open field for drug discovery of new anticancer agents whose
sources are the species that make up this genus. 
3. Momordica balsamina Linn. Momordica is a genus of
about 60 species of annual or perennial climbers herbaceous
or rarely small shrubs belonging to the family Cucurbitaceae,
natives of tropical and subtropical Africa and Asia, as well
as Australia. The genus attracted the attention of Professor
Maria-Jose Ferreira since one of its members, Momordica
charantia, was well-known in the traditional medicine
widely practiced in China as therapy for hypoglycemia
seemingly improving the rate of wound healing. The genus
Momordica has also provided a rich source of terpenoids
with activities against cancer cells. From the aerial parts of
Momordica balsamina, five new cucurbitane-type
triterpenoids (1-5) and two known analogues have been
isolated and characterized for cytotoxicity against human
breast cancer cells (MCF-7). Their structures were
determined by spectroscopic methods, including 2D NMR
experiments (COSY, HMQC, HMBC and NOESY). The new
compounds presented unusual oxidation patterns in the
cucurbitane skeleton at C-29 and C-12 of some of the
compounds isolated. Compounds 1-4, 6 and 7 were shown
to have high in vitro cytotoxicity against a human breast
cancer cell line (44). Four of these curcubitane-type
triterpenes compounds were studied for their inhibition of the
ABC transporter P-glycoprotein coded by the human ABCB1
gene transfected into mouse lymphoma cells. The evaluation
was conducted by flow cytometry using rhodamine 123 and
real-time fluorometry assessing accumulation of ethidium
bromide on a real-time basis. The most active compound that
inhibited efflux of ethidium bromide and rhodamine 123
from the ABCB1-transfected mouse lymphoma cell was 7-
methoxycucurbita-5,24-diene-3beta,23(R)-diol (44).
Interestingly, this compound has a minor effect on the
replication of the cell line used by Spengler et al. (44) and,
hence, we can deduce that it has little toxicity. Although the
genus has few species, similar studies should be considered
with the remaining unstudied species of this genus. 
Conclusion/Summary/Questions
There are some questions that require answers, however, prior
to serious consideration of adjuvant use of tripertinoids. A large
study that quantifies the ability of each reported active
tripertinoid to reverse resistance of members of a panel of
multidrug-resistant cancer cells to given anticancer agents (i.e.
inhibit the main efflux pump responsible for multidrug
resistance) is needed. The identified major active compounds
would also need to be evaluated for cytotoxic activity against
a panel of normal cells. Then, it would be possible to select for
clinical trial(s) bioactive tripertinoid compounds as adjuvants
for specific therapies of specific multidrug-resistant cancers. 
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